March 14, 2023
Sapience Therapeutics Receives IND Clearance from FDA to Proceed with Phase 1-2 Study of ST316 in Patients with Solid Tumors
January 26, 2023
Sapience Therapeutics to Present at the Guggenheim Healthcare Talks 2023 Oncology Day
December 1, 2022
Sapience Therapeutics Announces Appointment of Abi Vainstein-Haras, M.D. as Chief Medical Officer
November 10, 2022
Sapience Therapeutics Presents Data on the Immune Activating Function of ST101 at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
March 31, 2022
Sapience Therapeutics Expands Executive Team with Appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs
February 15, 2022
Sapience Therapeutics Strengthens Executive Team with Appointments of Marisa Frackman as Chief Financial Officer and Seth I. Rubin as General Counsel
February 3, 2022
Sapience Therapeutics to Present at Guggenheim Healthcare Talks, 2022 Oncology Conference
January 6, 2022
Sapience Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ST101
December 15, 2021
Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for Advanced Cutaneous Melanoma
December 9, 2021
Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at the 2021 San Antonio Breast Cancer Symposium
December 6, 2021
Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for the Treatment of Recurrent Glioblastoma Multiforme (GBM)
December 1, 2021
Sapience Therapeutics to Present at the RBC Capital Markets Healthcare Private Company Conference
November 10, 2021
Sapience Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference
September 13, 2021
Sapience Therapeutics Announces Poster Presentation on ST101 at the European Society for Medical Oncology (ESMO) Congress 2021
July 29, 2021
Sapience Therapeutics Commences Dosing in Final Dose-Escalation Cohort of Ongoing Phase 1-2 Study of ST101
May 18, 2021
Sapience Therapeutics Awarded SBIR Phase I Grant from National Institute of Allergy and Infectious Diseases
June 17, 2020
Sapience Therapeutics to Present Data on its Two Lead Programs at 2020 AACR Virtual Annual Meeting II
June 2, 2020
Sapience Therapeutics Announces FDA Acceptance of IND Application for ST101 in Advanced Cancer Indications
September 4, 2019
Sapience Therapeutics Builds Clinical Team with Appointment of Alice Bexon, MD, as Chief Medical Officer
March 14, 2019
Sapience Therapeutics to Present Poster on ST101 at the 2019 American Association for Cancer Research Annual Meeting
March 29, 2017